1) Warnes, CA : Transposition of the great arteries. Circulation 2006 ; 114 : 2699-2709
2) Maki, H et al : Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension. Int Heart J 2011 ; 52 : 323-326
2) 石塚尚子ほか : 修正大血管転位症の成人期臨床像. 心臓 1995 ; 27 : 970-976
3) Ogawa, A et al : Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 2014 ; 118 : 414-419
3) Khairy, P et al : PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease : developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Heart Rhythm 2014 ; 11 : e102-e165
4) Sitbon, O et al : Upfront triple combination therapy in pulmonary arterial hypertension : A pilot study. Eur Respir J 2014 ; 43 : 1691-1697
4) van Gelder, BM et al : Transseptal endocardial left ventricular pacing : an alternative technique for coronary sinus lead placement in cardiac resynchronization therapy. Heart Rhythm 2007 ; 4 : 454-460
5) Calvo, N et al : Endocardial left ventricular lead placement from the left subclavian vein approach. Europace 2014 ; 16 : 1857-1859
5) Akagi, S et al : Catecholamine support at the initiation of epoprostenol therapy in pulmonary arterial hypertension. Ann Am Thorac Soc 2014 ; 11 : 719-727
6) Rademakers, LM et al : Mid-term follow up of thromboembolic complications in left ventricular endocardial cardiac resynchronization therapy. Heart Rhythm 2014 ; 11 : 609-613
6) Fujino, T et al : Targeted therapy is required for management of pulmonary arterial hypertension after defect closure in adult patients with atrial septal defect and associated pulmonary arterial hypertension. Int Heart J 2015 ; 56 : 86-93
7) Kriebel, T et al : ICD Implantation in infants and small children : the extracardiac technique. Pacing Clin Electrophysiol 2006 ; 29 : 1319-1325
7) Simonneau, G et al : Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013 ; 62 : D34-D41
8) Myers, PO et al : Assessment of operability of patients with pulmonary arterial hypertension associated with congenital heart disease. Circ J 2014 ; 78 : 4-11
8) Kowalski, M et al : An alternative technique of implanting a nontransvenous implantable cardioverter-defibrillator system in adults with no or limited venous access to the heart. Heart Rhythm 2010 ; 7 : 1572-1577
9) Tahara, N et al : Successful shunt closure and improvement of hemodynamics in an ASD patient with severe pulmonary arterial hypertension and small shunt following a long-term use of bosentan. Int J Cardiol 2012 ; 158 : e38-e40
9) Cannon, BC et al : Innovative techniques for placement of implantable cardioverter-defibrillator leads in patients with limited venous access to the heart. Pacing Clin Electrophysiol 2006 ; 29 : 181-187
10) Bradley, EA et al : Usefulness of medical therapy for pulmonary hypertension and delayed atrial septal defect closure. Am J Cardiol 2013 ; 112 : 1471-1476
10) Burke, MC et al : Safety and efficacy of the totally subcutaneous implantable defibrillator : 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol 2015 ; 65 : 1605-1615
11) Galie, N et al : BREATHE-5 : Bosentan improves hemodynamics and exercise capacity in the first randomized placebo-controlled trial in Eisenmenger physiology. Chest 2005 ; 128 : 496S
12) Mukhopadhyay, S et al : Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome-a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis 2011 ; 6 : 424-431
13) Zhang, ZN et al : Oral sildenafil treatment for Eisenmenger syndrome : A prospective, open-label, multicentre study. Heart 2011 ; 97 : 1876-1881
14) D'Alto, M et al : Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2012 ; 155 : 378-382
15) Dimopoulos, K et al : Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010 ; 121 : 20-25
16) Iversen, K et al : Combination therapy with bosentan and sildenafil in Eisenmenger syndrome : A randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010 ; 31 : 1124-1131